Last reviewed 2026-04-21 · How we verify

Briviact (BRIVARACETAM)

Briviact works by binding to the synaptic vesicle glycoprotein 2A, reducing the release of neurotransmitters and stabilizing neuronal activity.

At a glance

Mechanism of action

The precise mechanism by which BRIVIACT exerts its anticonvulsant activity is not known. Brivaracetam displays high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect.

Approved indications

• Partial seizure

Common side effects

• somnolence and sedation
• dizziness
• fatigue
• nausea/vomiting symptoms
• constipation
• irritability

Key clinical trials

• Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (PHASE3)
• A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
• Epileptic Hippocampus in Alzheimer's Disease (PHASE1,PHASE2)
• A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
• Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (PHASE3)
• A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy (PHASE3)
• Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (PHASE1,PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.